Author

P. J. Jost

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Arner· 1 shared A. Boettcher· 1 shared A. Kostina· 1 shared A. M. Krackhardt· 1 shared B. Fehse· 1 shared B. Haller· 1 shared B. Klink· 1 shared B. Kuster· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Arner

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltration

C. Tretter, N. de Andrade Kraetzig, M. Pecoraro, S. Lange, P. Seifert, C. von Frankenberg, J. Untch, F. S. Dreyer, E. Braeunlein, M. Wilhelm, D. P. Zolg, T. Engleitner, S. Uhrig, M. Boxberg, K. Steiger, , A. M. Krackhardt

This study identifies RNA as a significant source of tumor-agnostic neoantigens, which correlate with T-cell infiltration in multiple cancer types.

bioRxiv · Sep 17, 2022Cancer Biology

Tyrosine kinase inhibitors trigger lysosomal damage-associated cell lysis to activate the NLRP3 inflammasome

E. Neuwirt, G. Magnani, T. Cikovic, A. Kostina, S. Wohrle, S. Flemming, N. J. Fischenich, B. S. Saller, O. Gorka, S. Renner, C. Agarinis, C. Parker, A. Boettcher, C. J. Farady, R. Backofen, , O. Gross

A small molecule screen identifies tyrosine kinase inhibitors that cause lysosomal damage, leading to cell lysis and NLRP3 inflammasome activation via K+ efflux.

bioRxiv · Feb 19, 2022 · PreprintImmunology

In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets

M. Carlet, K. Voelse, J. Vergalli, M. Becker, T. Herold, A. Arner, W.-H. Liu, V. Dill, B. Fehse, C. D. Baldus, L. Bastian, L. Lenk, D. M. Schewe, J. W. Bagnoli, P. J. Jost, , I. Jeremias

The paper develops an in vivo inducible RNAi system in patient-derived xenograft models to identify therapeutic targets in acute leukemias.

bioRxiv · May 2, 2020Cancer Biology

TNFR2 induced priming of NLRP3-inflammasome via RIPK1 leads to pyroptosis in XIAP deficient cells

J. Knop, L. M. Spilgies, S. Rufli, R. Reinhardt, L. Vasilikos, M. Yabal, P. J. Jost, H. Wajant, M. D. Robinson, T. Kaufmann, W. W.-L. Wong

The paper shows TNFR2 activation in XIAP-deficient cells leads to NLRP3 inflammasome priming and pyroptosis via RIPK1 and ROS, with implications for reducing IL-18 release in XLP-2 patients.

bioRxiv · Feb 15, 2019Immunology